[Congressional Record Volume 167, Number 222 (Thursday, December 30, 2021)]
[House]
[Page H7846]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]




                     EXECUTIVE COMMUNICATIONS, ETC.

   Under clause 2 of rule XIV, executive communications were taken from 
the Speaker's table and referred as follows:

       EC-3031. A letter from the Associate Director, Regulatory 
     Management Division, Environmental Protection Agency, 
     transmitting the Agency's final rule -- Pyflubumide; 
     Pesticide Tolerances [EPA-HQ-OPP-2020-0421; FRL-9282-01-
     OCSPP] received December 14, 2021, pursuant to 5 U.S.C. 
     801(a)(1)(A); Public Law 104-121, Sec. 251; (110 Stat. 868); 
     to the Committee on Energy and Commerce.
       EC-3032. A letter from the Associate Director, Regulatory 
     Management Division, Environmental Protection Agency, 
     transmitting the Agency's final action -- Findings of Failure 
     to Submit State Implementation Plan Revisions for the 2016 
     Oil and Natural Gas Industry Control Techniques Guidelines 
     for the 2015 Ozone National Ambient Air Quality Standards 
     (NAAQS) and for States in the Ozone Transport Region [EPA-HQ-
     OAR-2021-0868; FRL-9251-01-OAR] received December 14, 2021, 
     pursuant to 5 U.S.C. 801(a)(1)(A); Public Law 104-121, Sec. 
     251; (110 Stat. 868); to the Committee on Energy and 
     Commerce.
       EC-3033. A letter from the Associate Director, Regulatory 
     Management Division, Environmental Protection Agency, 
     transmitting the Agency's final rule -- MCPA; Pesticide 
     Tolerances [EPA-HQ-OPP-2020-0691; FRL-9273-01-OCSPP] received 
     December 14, 2021, pursuant to 5 U.S.C. 801(a)(1)(A); Public 
     Law 104-121, Sec. 251; (110 Stat. 868); to the Committee on 
     Energy and Commerce.
       EC-3034. A letter from the Associate Director, Regulatory 
     Management Division, Environmental Protection Agency, 
     transmitting the Agency's final rule -- a-Terpineol (CAS No. 
     98-55-5); Tolerance Exemptions [EPA-HQ-OPP-2021-0659; FRL-
     9322-01-OCSPP] received December 14, 2021, pursuant to 5 
     U.S.C. 801(a)(1)(A); Public Law 104-121, Sec. 251; (110 Stat. 
     868); to the Committee on Energy and Commerce.
       EC-3035. A letter from the Associate Director, Regulatory 
     Management Division, Environmental Protection Agency, 
     transmitting the Agency's final rule -- Mefentrifluconazole; 
     Pesticide Tolerances [EPA-HQ-OPP-2020-0538; FRL-9194-01-
     OSCPP] received December 14, 2021, pursuant to 5 U.S.C. 
     801(a)(1)(A); Public Law 104-121, Sec. 251; (110 Stat. 868); 
     to the Committee on Energy and Commerce.
       EC-3036. A letter from the Director, Office of Acquisition 
     Policy, Office of Government-wide Policy, General Services 
     Administration, transmitting the Administration's summary 
     presentation of final rules -- Federal Acquisition 
     Regulation; Federal Acquisition Circular 2022-02; 
     Introduction [Docket No.: FAR-2021-0051, Sequence No. 6] 
     received December 20, 2021, pursuant to 5 U.S.C. 
     801(a)(1)(A); Public Law 104-121, Sec. 251; (110 Stat. 868); 
     to the Committee on Oversight and Reform.
       EC-3037. A letter from the Director, Office of Acquisition 
     Policy, Office of Government-wide Policy, General Services 
     Administration, transmitting the Administration's final rule 
     -- Federal Acquisition Regulation; Technical Amendments [FAC 
     2022-02; Item II; Docket No.: FAR-2021-0052; Sequence No. 4] 
     received December 20, 2021, pursuant to 5 U.S.C. 
     801(a)(1)(A); Public Law 104-121, Sec. 251; (110 Stat. 868); 
     to the Committee on Oversight and Reform.
       EC-3038. A letter from the Director, Office of Acquisition 
     Policy, Office of Government-wide Policy, General Services 
     Administration, transmitting the Administration's final rule 
     -- Federal Acquisition Regulation: Update to Certain Online 
     References in the FAR [FAC 2022-02; FAR Case 2021-003; Item 
     I; Docket No.: FAR-2021-0003; Sequence No. 1] (RIN: 9000-
     AO21) received December 20, 2021, pursuant to 5 U.S.C. 
     801(a)(1)(A); Public Law 104-121, Sec. 251; (110 Stat. 868); 
     to the Committee on Oversight and Reform.
       EC-3039. A letter from the Director, Office of Acquisition 
     Policy, Office of Government-wide Policy, General Services 
     Administration, transmitting the Administration's small 
     entity compliance guide -- Federal Acquisition Regulation; 
     Federal Acquisition Circular 2022-02; Small Entity Compliance 
     Guide [Docket No.: FAR-2021-0051, Sequence No. 6] received 
     December 20, 2021, pursuant to 5 U.S.C. 801(a)(1)(A); Public 
     Law 104-121, Sec. 251; (110 Stat. 868); to the Committee on 
     Oversight and Reform.
       EC-3040. A letter from the Regulations Coordinator, Centers 
     for Medicare and Medicaid Services, Department of Health and 
     Human Services, transmitting the Department's final rule -- 
     Medicare Program: Hospital Outpatient Prospective Payment and 
     Ambulatory Surgical Center Payment Systems and Quality 
     Reporting Programs; Price Transparency of Hospital Standard 
     Charges; Radiation Oncology Model [CMS-1753-FC] (RIN: 0938-
     AU43) received December 9, 2021, pursuant to 5 U.S.C. 
     801(a)(1)(A); Public Law 104-121, Sec. 251; (110 Stat. 868); 
     jointly to the Committees on Energy and Commerce and Ways and 
     Means.

                          ____________________